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ABSTRACT 
The development of effective molecular probes to detect and image the levels of oxidative stress in 
cells remains a challenge. Herein we report the design, synthesis and preliminary biological 
evaluation of a novel optical probe to monitor oxidation of thiol groups in cysteine-based 
phosphatases (CBPs). Following orthogonal protecting approaches we synthesised a new vanadyl 
complex designed to bind to CBPs. This complex is functionalised with a well-known dimedone 
derivative (to covalently trap sulfenic acids, SOHs) and a coumarin-based fluorophore for optical 
visualization. We show that this new probe efficiently binds to a range of phosphatases in vitro with 
nanomolar affinity. Moreover, preliminary flow cytometry and microscopy studies in live HCT116 
cells show that this probe can successfully image cellular levels of sulfenic acids – one of the species 
resulting from protein oxidative damage.  
 
INTRODUCTION 
A large number of proteins and enzymes are chemoselectively targeted by reactive oxygen species 
(ROS) via oxidation of cysteine residues.1,2 Several studies have proposed oxidation as an important 
mechanism to regulate and control, as well as alter, essential cellular functions.2-4 The heterogeneous 
family of cysteine-based phosphatases (CBPs), also referred to as ‘protein tyrosine phosphatases’ 
(PTPs), is known to undergo oxidative modifications that lead to changes in their activity which in 
turn have an impact on cell growth and homeostasis.5,6 It has been demonstrated that the catalytic 
cysteine of CBPs (which has a low pKa) can be easily turned into a cysteine thiolate and subsequently 
oxidized by reaction with ROS (mainly H2O2) leading to the inhibition of its phosphatase activity.
7 
Among the different forms of thiol oxidation, transient and reversible sulfenic acids (SOHs) are the 
first products to form in ROS-mediated oxidation of a generic cysteine. This process has been 
proposed to preserve enzymes from further reaction due to excessive ROS stimuli.8,9 Recent studies, 
have shown that the dynamic nature of SOH modifications (i.e. reversibility, allowing thiol 
regeneration) is a way to regulate CBP activity. Furthermore, this is a marker of initial protein 
oxidative damage, which has been associated to pathologies such as cancer, diabetes and 
neurodegenerative disorders.1,10 Consequently, sulfenylation is considered a prominent post-
translational modification (PTM),5,8,11 leading to a variety of biochemical transformations and 
additional protein thiol oxidation forms (e.g. disulfide bond, S-glutathiolation and, cyclic 
sulfonamide, as well as largely irreversible sulfinic and sulfonic acids).  
Chemical probes for SOH detection represent promising means to elucidate signalling pathways and 
regulatory mechanisms involving cysteine oxidation and redox regulation in CBPs. Therefore, 
extensive work has gone into developing targeted tools to identify sulfenic residues.12-15 By exploiting 
the unique chemical reactivity of this sulfur species, several small-molecules have been recently 
developed which react with SOH cysteines both in vitro and in cells. A family of molecules which 
has been widely used for this purpose are derivatives of 5,5-dimethyl-1,3-cyclohexanedione, also 
known as dimedones (see ‘SOH targeting group’ in Figure 1c).12-19  
 
Figure 1. Rational design of trifunctional optical probe. (a) Chemical structure of the previously 
validated CBP inhibitor [VO(pic)2];
23-25 (b) Chemical structure of a previously reported optical 
probe based on coupling dansyl fluorophore with a VO(pic)2 core;
26 (c) Chemical structure of the 
trifunctional probe reported in this study containing a CPB-targeting moiety (i.e. VO(pic)2), a 
coumarine-based fluorophore for imaging and a dimedone derivative to target SOH. 
 
However, selective and potent tools to monitor sulfenic modifications on a specific family of enzymes 
are still largely unavailable and improvements to the existing methods for generic SOH identification 
are required.20 Carroll’s group recently reported the only example of an optical probe able to 
selectively detect oxidative modifications of PTPs (in particular YopH and PTP1B) with micromolar 
affinity.21 While this probe has provided interesting insights into the oxidative processes of PTPs, it 
relies on an indirect visualization method via streptavidin/biotin visualization.21,22 
Previously, vanadyl complexes such as [VO(pic)2] (Figure 1(a)) have been shown to be very good 
inhibitors for phosphatases,23-25 and consequently, VO(pic)2 represents a good candidate to use as 
targeting motif for the enzymes of interest. More recently, we have successfully modified the 
dipicolinic vanadyl core through introduction of a bridge between the two picolinic residues.26 This 
allowed us to further functionalize the vanadyl complex and introduce a dansyl fluorophore for optical 
visualization (Figure 1(b)). Most importantly, the introduction of the fluorophore did not have a major 
impact on the activity of the [VO(pic)2] towards CBPs (the functionalized complex retained the 
nanomolar affinity for CBPs).26  
Herein we report the further chemical manipulation carried out on the [VO(pic)2] scaffold through 
the design, synthesis and preliminary biological evaluation of a new optical probe, with the ultimate 
aim to selectively detect and directly visualize SOH oxidation on CBPs. In addition to the [VO(pic)2] 
core for CBP targeting, the new vanadyl complex contains a dimedone derivative and a coumarine-
based fluorophore (Figure 1(c)), for both SOH detection (under oxidative conditions) and optical 
visualization in vitro and in cellulo.  
 
 
 
 
RESULTS AND DISCUSSION 
Synthesis of the trifunctional optical probe  
The syntheses of the target dimedone-coumarine ligand 14 and the corresponding vanadyl complex 
16 are outlined in Schemes 1 and 2 respectively. Two synthetic routes were originally investigated to 
prepare the protected precursor 14 starting with the bridged di-picolinic compound 1.26 The full 
synthetic design is based on a tri-orthogonal strategy by using in parallel two lysine scaffolds (i.e. 
Nα-Boc-Nε-Fmoc-L-Lys and Nα-Fmoc-Nε-Boc-L-Lys) with swapped protections on the amino 
groups (Scheme 1). This approach allowed us to determine the most useful protecting group in each 
position and the correct de-protection order in the synthesis of the methyl-protected compound 14.   
  
Scheme 1. Tri-orthogonal approach for the synthesis of fully protected precursor 14. Reagents and 
conditions: a) Nα-Boc-Nε-Fmoc-L-Lys (1.0 equiv), HATU (1.2 equiv), DIPEA (3.5 equiv), DMF, 
N2, 7 h, rt; b) 60 °C; piperidine/CH3CN 1:4, o/n, rt; c) HOBt (1.0 equiv), Et3N (1.4 equiv), EDC 
(1.4 equiv), 4 or 8 (1.1-1.4 equiv), DMF, N2, 48 h, rt;  d) TFA/CH2Cl2 1:2, 2 h, rt; e) TsOH (0.05 
equiv), CH3OH, 1 h, rt; f) Nα-Fmoc-Nε-Boc Lys (1.0 equiv), TBTU (1.5 equiv), DIPEA (3 equiv), 
DMF, N2, 6 h, rt; g) NHS (1.0 equiv), DCC (1.1 equiv), DMF, 5 h, 0 °C → rt; h) DMAP (0.1 
equiv), DIPEA (2.0 equiv), 13 (0.95 equiv), CH2Cl2, N2, 22 h, rt. 
 
In the first route investigated, compound 1 was firstly reacted with Nα-Boc-Nε-Fmoc-L-Lys to yield 
compound 2, using HATU (2-(7-aza-1H-benzotriazol-1-yl)-N,N,N’,N’-tetramethylaminium 
hexafluorophosphate) as coupling reagent. After standard piperidine-mediated Fmoc removal, 
compound 3 was converted into 5 via amide coupling with 7-methoxycoumarin-3-carboxylic acid 
(4), in the presence of EDC, HOBt and Et3N. Standard Boc removal using TFA afforded 6 which was 
directly reacted with 3-methoxy-5-oxocyclohex-3-ene-1-carboxylic acid 8 (i.e. ‘protected dimedone 
residue’, obtained following a literature procedure13) to yield compound 14. However, this synthetic 
approach gave very low yields both for several of the reaction intermediates and for the final product 
14 (ca. 6%). Therefore, we explored a different synthetic approach to obtain higher yields of 14.  We 
used Nα-Fmoc-Nε-Boc-L-Lys as protected scaffold to carry out the first reaction on the dipicolinic 
starting material 1 (Scheme 1). The coupling was performed with TBTU (2-(1H-benzotriazol-1-yl)-
N,N,N’,N’-tetramethylaminium tetrafluoroborate) and DIPEA in anhydrous DMF and resulted in a 
good conversion of 1 into intermediate  9 (93% yield). Fmoc was removed and 10 was coupled with 
the protected dimedone 813 using HOBt, EDC and Et3N, to give 11 in nearly quantitative yield. 
Removal of Boc afforded intermediate 12 which was then used to introduce the 7-methoxycoumarin 
fluorophore. Activation of the carboxylic group of 4 via the succinimidyl ester 1327 was carried out, 
allowing the synthesis of 14 in 98% yield.  The significantly higher yields of 14, and the easier 
purification and higher yields of the reaction intermediates, indicate that the second synthetic 
approach (going from 9 to 14) is significantly more efficient than the first.  
A basic/acidic one-pot hydrolysis was subsequently performed to convert 14 into the desired ligand 
15 (Scheme 2), using sequentially LiOH and HCl to remove the methyl protections on picolinic esters 
and dimedone. Compound 15 was purified through preparative HPLC and used in the final 
complexation reaction with VOSO4 to obtain the final dimedone-substituted optical probe 16 
(Scheme 2) as a dark green solid.  
 
 Scheme 2. Synthesis of the vanadyl complex 16. 
 
The formation of 16 was confirmed by mass spectrometry (ESI and MALDI - see Experimental 
section below and Section 4 in Supplementary Information for spectral data) which showed the 
molecular peak at 904 a.m.u. [M+Na]+ and 880 a.m.u. [M]+, respectively, and IR spectroscopy which 
showed the presence of a strong peak at 969 cm-1 (assigned to V=O). The presence of the 
vanadium(IV) centre was also confirmed by Electron Spin Resonance (ESR) studies in the solid state 
and solution (Figure 2 – see below for further discussion about ESR characterisation). Elemental 
analysis confirmed the formulation and purity of the complex. The vanadyl complex 16 also retained 
the optical properties of the coumarin moiety with an emission profile similar to the corresponding 
free ligand 15 (i.e. λem = 409 for ligand 15 and 407 nm for complex 16; Sections 3 and 4 in Supporting 
Information).  
To ensure that the L-Lys residue retained its configuration during standard coupling steps,28 we 
performed enantio-resolution studies on 15 using three different chiral stationary phases (i.e. amylose 
tris(3,5-dimethylphenylcarbamate), cellulose tris(4-methylbenzoate), and cellulose tris(3,5-
dimethylphenylcarbamate) in combination with two mobile phase systems (i.e. n-hexane/isopropanol 
and acetonitrile/isopropanol).29 These studies confirmed that racemization does not occur and the full 
synthetic route shows high stereoselectivity (Figure S1, Supporting Information).  
Before carrying out cellular studies with complex 16, it was of interest to establish its stability to 
oxidation under physiological conditions. To this end, we recorded the ESR spectra of 16 (at different 
times over 1 week) both as a solid and in solution using buffered aqueous media and 10% DMSO – 
which are the same solvents used to prepare the samples for the cellular studies described below. The 
sample of 16 used for these studies was prepared and stored under nitrogen prior to the ESR studies 
– which were carried out under aerobic conditions. As can be seen in Figure 2, the spectra at time 
zero and after 48 hours (both in the solid state and in solution) show clearly the presence of a 
vanadium(IV) species. However, after one week the ESR spectrum of the sample indicates that there 
is little vanadium(IV) left which is likely to be due to the oxidation of the metal centre to 
vanadium(V). This is not unusual for this type of complexes as has been previously reported by 
others.30, 31  
 
 
(a) (b)
Figure 2. ESR spectra at 100 K for complex 16 (1 mg) suspended in McCoy’s media (+10% DMSO, 
200 μL). (a) Solid sample (4 scans) and (b) solution (16 scans) analysed at time 0 (i.e. the time when 
the complex was mixed with the solvent), 48 hours and after 1 week. 
 
To assess further the possible oxidation of vanadium(IV) to vanadium(V), we recorded the 51V NMR 
spectrum of a solution of complex 16 that had been exposed to air for 72 hours.  This spectrum showed 
the presence of two very broad bands centred at ca. -490 and -700 ppm (see Figure S2). This NMR 
study indicates that vanadium(V) species formed over this period of time; however, the very broad 
peaks suggest that paramagnetic species (i.e. vanadium(IV)) are likely to be also present – which 
would be consistent with the ESR studies discussed above.  
 
In vitro phosphatase inhibition studies. As discussed above, VO-picolinate moieties have been 
previously shown to bind to a range of phosphatases (including CBPs) and inhibit their activity. 
Therefore, we were interested in establishing whether the new multi-functional probe 16 would still 
retain its ability to inhibit a selection of CBPs. For this, IC50 values were determined using 3-O-
methylfluorescein phosphate (OMFP) as a substrate (see Experimental Section and Figure S4-6, 
Supporting Information).32 These studies showed that 16 has a mid to high nanomolar inhibitory 
activity (IC50= 99-221 nM, Table 1; Figure S5 and S6, Supporting Information) for a group of CBPs, 
including both tyrosine and lipid phosphatases (i.e. PTP1B, VHR, SHP-2, LMW-PTP and PTEN, see 
Table 1 for abbreviation). These observations are in agreement with our earlier investigation on the 
dansyl-labelled [VO(pic)2] derivative (Figure 1(b)), which possessed similar potencies against PTPs 
and PTEN.26  However, the IC50 values for 16 against VHR and PTP1B are around two-fold higher 
than for PTEN, SHP2 and LMW-PTP, whereas the dansyl-labelled [VO(pic)2] derivative (see Figure 
1(b)) favoured PTP1B, VHR and SHP2. This observation suggests that the new complex could have 
some selectivity towards specific CBPs compared to others, inhibiting better phosphatases with a 
large catalytic pocket (e.g. PTEN),33 or interacting with specific secondary substrate binding sites 
(e.g. in the case of SHP2 and LMW-PTP).34  
 
 
Table 1. Inhibitory activity (IC50, nM) of dimedone-based VO(pic)2 complex 16 toward PTEN (= 
phosphatase and tensin homolog), VHR (= dual specificity protein phosphatase 3), SHP-2 (= Src 
homology region 2 domain-containing phosphatase-2), LMW-PTP (= low molecular weight protein 
tyrosine phosphatase), and PTP1B (= protein-tyrosine phosphatase 1B). 
 
 PTEN VHR SHP2 LMW-PTP PTP1B 
16 99±13 199±15 113±2 106±4 221±12 
 
 
Oxidation response in live cells. Having demonstrated the nanomolar affinity of 16 for a group of 
phosphatases, we next carried out flow cytometry and microscopy studies to determine whether the 
new probe would respond to changes in sulfenic oxidative modifications produced in cultured cells. 
Thus, probe 16 was first incubated (for 1, 6 and 24 hours) with live HCT116 cells, followed by flow 
cytometry to determine if 16 was cell permeable. However, the results showed that under these 
conditions the probe is unable to enter live cells (Figure S7, Supporting Information). Consequently, 
we next investigated cellular uptake in the presence of the phorbol ester PMA (i.e. phorbol 12-
myristate-13-acetate), a fatty acid agent known to stimulate endocytosis.35 We first determined cell 
viability using the MTS assay by incubating HCT116 cells with PMA (100 nM) and with 16 at 
different times (0 to 48 hours) and concentrations (0 to 200 μM). As can be seen in Figure S8, the 
viability of cells is not significantly compromised at incubations times of up to 7.5 h – even when the 
concentration of 16 was as high as 200 μM.  
HCT116 cells were co-incubated for 1 and 6 hours with probe 16 (200 µM) and PMA (100 nM). In 
the presence of PMA, flow cytometry and microscopy analysis indicated an effective uptake of 16 in 
HCT116 cells at 6 hours (Figures S9 and S10, Supporting Information).  
Having established a protocol to permeabilize live cells, we then carried out studies to assess the 
suitability of probe 16 to detect oxidative damage (see Experimental Section). Therefore, cells were 
co-treated with PMA (100 nM) and 16 (200 µM) for 6 h, followed by treatment with H2O2 (1 mM, 
30 min) to generate protein SOHs. As can be seen in Figures 3 and S11 (Supporting Information) 
cells treated with H2O2 gave significantly higher fluorescence values with respect to controls (i.e. 0 
mM 16 and 0 mM H2O2), suggesting that the optical probe is able to detect the oxidation produced 
upon addition of the oxidising agent.  
 
 
Figure 3. Flow cytometry analysis of HCT116 cells incubated with 16 under oxidative conditions. 
Live HCT116 cells were co-treated with 100 nM PMA and 200 μM 16 for 6 hours following by 
addition of 0 or 1 mM H2O2 for 30 min. A) Dotplot of 16 treated cells with (Green) and without 
(Blue) 1 mM H2O2 represent increase in fluorescence intensity upon treatment with H2O2. Untreated 
cells are shown in red. B) Increase of the median fluorescence intensity (MFI) observed in cells 
treated with 1 mM H2O2.  Autofluorescence was measured in the absence of 16 (shown as control). 
MFI data are presented as mean ± SE of three independent experiments. 15000 cells were measured 
for each analysis. Significant differences (two-way ANOVA) to the control data are indicated by 
stars (***p < 0.001).  
 
 Employing the conditions used for flow cytometry it was also possible to image by fluorescence 
microscopy the oxidative formation of SOHs in HCT116 cells. Treatment was carried out on live 
cells which were then fixed and thoroughly washed to remove any unbound species (e.g. unreacted 
probe 16). These experiments showed that there is some cellular uptake of 16 in live HCT116 cells 
(Figure 4(c), control 3) which is significantly increased upon treatment with H2O2 indicating 
successful crosslinking of the dimedone functionality in the cellular environment (Figure 4(d), 
oxidation experiment). As a control, we treated a sample of 16 (in buffer) with H2O2 for 30 minutes 
and compared its emission before and after treatment (see Figure S12). We observed an increase of 
the emission intensity after H2O2 treatment which could be due to a change in the oxidation state of 
the vanadium from V+4 (paramagnetic) to V+5 (diamagnetic). However, this on its own would not 
explain the great increase in emission observed in the H2O2-treated cells since, after treatment, cells 
were fixed and thoroughly washed to remove any unbound compound (either free 16 or unbound 
derivatives such as a vanadium(V) complex generated by oxidation with H2O2). 
 
Figure 4. Fluorescence microscopy images showing uptake of 16 (blue) by live HCT116 cells and 
increase of fluoresce during ongoing oxidation (i.e. H2O2). (a) Control 1: no 16, no H2O2. (b) 
Control 2: no 16, 1 mM H2O2 for 30 min. (c) Control 3: 200 μM 16 (co-incubated with 100 nM 
PMA) for 6 hours, no H2O2. (d) ‘Oxidation sensing’ experiment: 200 μM 16 (co-incubated with 100 
nM PMA) for 6 hours, 1 mM H2O2 for 30 min. Two representative images are presented for each 
treatment and comparison with merge channel images for 16 incubation experiments. Quantification 
of fluorescence signal was performed with FIJI. Data for the quantification are reported as mean ± 
SE and were obtained from a minimum of 3 independent experiments counting a total number of 12 
cells for each treatment. Significant differences (5% cut-off for significance) to the control data are 
indicated by stars (***p < 0.001). 
 
CONCLUSION 
A multi-step synthetic protocol has been developed to prepare the new multifunctional probe 16. This 
probe contains a validated CBP-targeting motif (i.e. the VO(pic)2), a well-established SOH-reactive 
group (i.e. dimedone derivative) and an optical label (i.e. coumarine derivative) for in vitro and 
cellular imaging. To obtain this probe, a synthetic approach was performed where methyl-, Fmoc- 
and Boc- protecting groups were integrated into a tri-orthogonal protecting strategy, which proceeded 
with high enantioselectivity (i.e. L-Lys residue retains its chiral configuration). The reactions occur 
smoothly, leading to good yields of all the intermediates, and the overall mild conditions suggest that 
this procedure could be useful in complex molecule synthesis and related synthetic applications, 
relevant to picolinic acid functionalization in coordination chemistry research.36 Our in vitro data 
indicates that 16 retains the nM affinity of the ‘arrowhead’ towards CBPs (analogous to recent results 
with the simpler VO(pic)2 compound, shown in Figure 1(a)).
26 We have also demonstrated by 
preliminary flow cytometry and microscopy that the trifunctional probe can be taken up by live 
HCT116 cells (using a permeabilizing agent) and detect total changes in SOH levels upon treatment 
with H2O2. While our current data cannot confirm that CBPs are indeed being targeted inside the cell, 
it provides a first step towards the development of protein-selective intracellular probes to assess 
oxidative damage. Moreover, the established synthesis allows additional labelling methods (e.g. 
introduction of more emissive fluorophores) for further imaging approaches. However, it should be 
noted that while the vanadium(IV) centre in 16 does not oxidise significantly under aerobic conditions 
within 48 hours, this is not the case under longer exposure times (between 3 and 7 days). Therefore, 
compound 16 might undergo redox changes once it is taken up by cells exposed to oxidative 
conditions (with H2O2). Future studies will aim to explore this in more detail. 
 
 
EXPERIMENTAL DETAILS 
General Considerations. All reagents were purchased from chemical suppliers and used without 
further purification, unless otherwise mentioned. Room temperature refers to ambient temperature. 
Yields refer to chromatographically and spectroscopically pure compounds unless otherwise stated. 
Where possible, reactions were monitored by thin layer chromatography (TLC) performed on 
commercially available glass plates pre-coated with Merck silica gel 60 F254 or Merck silica gel 60 
RP-18 F254s. Visualisation was by the quenching of UV fluorescence (λmax= 254/365 nm) and by 
staining with iodine or potassium permanganate. All flash chromatography was carried out using 
slurry packed Merck 9325 Keiselgel 60 or Aldrich C18-reverse phase silica gel. Solid-state infrared 
spectra were recorded neat on a Perkin–Elmer Spectrum 100 FT-IR spectrometer (operating region 
4000 to 400 cm−1) with internal referencing. Selected absorption maxima (λmax) are reported in 
wavenumbers (cm–1). Melting points were obtained using a Gallenkamp Melting Point apparatus and 
are uncorrected. Nomenclatures do not follow the IUPAC naming system. 1H, 13C, DEPT, HSQC, 
and COSY NMR spectra were recorded using an internal deuterium lock at ambient probe 
temperatures on a Bruker DRX-400 (400 MHz) instrument. Chemical shifts (δ) are quoted in ppm, to 
the nearest 0.01 ppm (for 1H NMRs), or 0.1 ppm (for 13C NMRs), and are referenced to the residual 
non-deuterated solvent peak. Coupling constants (J) are reported in Hertz (Hz) to the nearest 0.5 Hz. 
Data are reported as follows: chemical shift, multiplicity (br= broad; s= singlet; d= doublet; t= triplet; 
m= multiplet, or as a combination of these, e.g. dd, dt, etc.), integration, assignment and coupling 
constant(s). Assignments were determined either on the basis of unambiguous chemical shift or 
coupling pattern, by patterns observed in 2D experiments (1H-1H COSY and HSQC, supported by 
DEPT) or by analogy to fully interpreted spectra for related compounds. Diastereotopic protons are 
assigned as CH-H. 51V NMR spectra were recorded on a Bruker Avance 500 MHz instrument 
(scanning from 1400 to -2600 ppm) and using a sample prepared by dissolving 3 mg of the complex 
in ca. 400 μL of DMSO-d6. 51V chemical shifts were referenced relative to neat sodium orthovanadate 
as the external standard. X-band ESR measurements were performed at 100 K using an X/Q-band 
Bruker Elexsys E580 Spectrometer (Bruker BioSpin GmbH, Germany) equipped with a closed-cycle 
cryostat (Cryogenic Ltd, UK) and a split-ring resonator with 2 mm sample access (ER 4118X-MS2). 
ESR samples were prepared by suspending 1 mg of the vanadium complex in 200 μL of McCoy’s 
media (+10% DMSO p.a. grade) at room temperature. The sample was then loaded into 100mm Q 
Band Suprasil EPR Tubes (Wilmad-LabGlass) and flash-frozen in liquid nitrogen. Liquid 
chromatography–mass spectrometry (LC-MS) experiments were performed on Waters Aquity UPLC 
I-CLASS coupled with Waters LCT Premier (operating in ES+ or ES- mode), unless otherwise stated. 
High resolution masses (HR-MS) for accurate mass determination were performed on the same 
equipment and samples referenced against Leucine Enkaphalin or Sulfadimethoxine. For analytical 
HPLC, a Waters BEH Acquity C18 (50mm x 2.1mm) column was used and the mobile phase was 
composed of solvent A (99.9% Water, 0.1% Formic Acid) and solvent B (99.9% Acetonitrile, 0.1% 
Formic Acid) used in a linear gradient (time= 0 min, 95%A and 5%B; time= 3.2 min, 5%A and 95%B; 
time= 3.5 min, 95%A and 5%B; total run time 4 min). The sample solutions were prepared at a 
concentration of 0.1 mg/1 mL. The injection volume was 10µL, the flow rate was 0.5mL/min, the 
column temperature was 40 °C, and the UV detector wavelength was fixed at 210 to 280 nm. The 
values of retention time (tR) are given in minutes. Unless otherwise mentioned, electron spray 
ionisation (ESI) conditions were as follow: 2kV (ES+) and 2.5kV (ES-) capillary voltage; 30 V (ES+) 
and 150 V (ES+) sample cone voltage; 2.1kV MCP Voltage; 350 °C desolvation temperature; 120 °C 
source temperature; 10 L/h cone gas flow (N2); 400 L/h desolvation gas flow (N2). Mass values are 
reported within the error limits of ±5 ppm mass units. MALDI analyses were performed using 
MicroMass MALDI microMX TOF operating in reflectron mode using a 337nm nitrogen laser. 
Preparative HPLC purifications were performed using H2O:CH3OH (gradient from 95:5 to 5:95, over 
18 min). The solvents were degassed and supplemented with 0.1% formic acid prior to use. HPLC 
platform consisted of a Waters RP-HPLC system (Waters 2767 autosampler for sample injection and 
collection; Waters 515 HPLC pump to deliver the mobile phase to the source; XBridge C18 columns 
with dimensions 19 mm x 100 mm) coupled to a Waters 3100 mass spectrometer (with ESI in positive 
and negative modes) and a Waters 2998 Photodiode Array (with detection between 200-600 nm). 
Microanalyses (C, H, and N) were performed by Mr. Alan Dickerson (University of Cambridge) and 
results are within ±0.4% of the theoretical values. Dimethyl-5,5'-{azanediylbis[(ethane-2,1-
diyl)oxy]}dipicolinate 1,26 3-methoxy-5-oxocyclohex-3-ene-1-carboxylic acid 813 and N-
succinimidyl ester of 7-methoxycoumarin-3-carboxylic acid 1327 were prepared by literature 
procedures.  
Boc/Fmoc-dipicolinate (2). HATU (1.35 g, 3.55 mmol) and DIPEA (1.85 mL, 10.64 mmol) were 
sequentially added to a solution of 1 (1.11g, 2.96 mmol) and Nα-Boc-Nε-Fmoc-L-Lys (1.39 g, 2.96 
mmol) in anhydrous DMF (20.0 mL) and the reaction was stirred for 7 h at 60 °C under N2 
atmosphere. The solvent was removed under reduced pressure and the mixture was directly purified 
by flash column chromatography (eluent: CH2Cl2/CH3OH 95:5) to yield 450 mg (18.4% yield) of 2 
as a yellowish viscous oil. 1H NMR (400 MHz, CDCl3) δ 8.35 (dd, 2H, ArH pic, J= 10.4 Hz, J= 2.8 
Hz), 8.07 (t, 2H, ArH pic, J= 8.0 Hz), 7.75 (d, 2H, ArH Fmoc, J= 7.6 Hz), 7.57 (d, 2H, ArH Fmoc, 
J= 6.8 Hz), 7.38 (dd, 2H, ArH Fmoc, J= 6.8 Hz, J= 7.6 Hz), 7.29 (td, 2H, ArH Fmoc, J= 6.4 Hz, J= 
1.2 Hz), 7.24-7.27 (m, 1H, ArH pic), 7.22 (dd, 1H, ArH pic, J= 5.6 Hz, J= 2.8 Hz), 5.20-5.25 (m, 1H, 
CHNH), 4.88 (exch br t, 1H, NH), 4.73-4.78 (m, 1H, CHCH2O), 4.17-4.37 (m, 6H, 2 x CH2CH2O + 
CHCH2O), 4.09-3.98 (m, 3H, NCH2CH2O + NCH-HCH2O), 3.97 (s, 6H, OCH3), 3.96 (s, 3H, OCH3), 
3.68-3.73 (m, 1H, NCH-HCH2O), 3.10-3.18 (m, 2H, (CH2)2CH2N), 1.41-1.67 (m, 15H, CH(CH2)3 + 
(CH3)3 Boc). LC-MS (ESI) calcd. for C44H51N5O11 825.9 (MW), found m/z 826.4 [M+H]
+, tR= 2.4. 
Amine dipicolinate (3). Intermediate 2 (450.0 mg, 0.54 mmol) was dissolved in CH3CN (8.0 mL), 
piperidine (2.0 mL) was dropwise added and the reaction was stirred overnight at room temperature. 
After evaporation of the solvent under vacuum, the mixture was purified by flash column 
chromatography (eluent: CH2Cl2/CH3OH 9:1) giving 170.0 mg (52.1% yield) of 3 as a pale yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 8.32 (dd, 2H, ArH pic, J= 13.6 Hz, J= 2.8 Hz), 8.06 (t, 2H, ArH 
pic, J= 8.8 Hz), 7.30 (dd, 1H, ArH pic, J= 6.0 Hz, J= 2.8 Hz), 7.22 (dd, 1H, ArH pic, J= 5.6 Hz, J= 
2.8 Hz), 6.13 (exch br t, 1H, NH), 5.27-5.33 (m, 1H, CHNH), 4.70-4.77 (exch br m, 2H, NH2), 3.95-
4.34 (m, 6H, 2 x CH2CH2O + NCH2CH2O), 3.94 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 3.66-3.71 (m, 
1H, NCH-HCH2O), 3.41-3.48 (m, 1H, NCH-HCH2O), 3.07-3.29 (m, 2H, (CH2)2CH2N), 1.30-1.70 
(m, 15H, CH(CH2)3 + (CH3)3 Boc). LC-MS (ESI) calcd. for C29H41N5O9 603.6 (MW), found m/z 
604.3 [M+H]+, 302.9 [M+2H/2]+, tR= 1.3. 
Boc-dipicolinate (5). HOBt (37.8 mg, 0.28 mmol), Et3N (0.05 mL, 0.39 mmol) and EDC (0.07 mL, 
0.39 mmol) were sequentially added to a stirred solution of 7-methoxycoumarin-3-carboxylic acid 4 
(75.0 mg, 0.34 mmol) in anhydrous DMF (2.0 mL). Intermediate 3 (170.0 mg, 0.28 mmol) was added 
and the reaction was carried out for 48 h at room temperature under N2 atmosphere. After removal of 
the solvent under vacuum, the crude mixture was purified by flash column chromatography (eluent: 
CH2Cl2/CH3OH 95:5) to yield 5 (85.0 mg, 37.7% yield) as an oil. 
1H NMR (400 MHz, CDCl3) δ 8.67 
(dd, 1H, ArH coum, J= 2.8 Hz, J= 1.6 Hz), 8.34 (dd, 2H, ArH pic, J= 12.8 Hz, J= 2.8 Hz), 8.07-8.14 
(m, 3H, ArH pic (2) + coum (1)), 7.94 (dd, 1H, ArH coum, J= 7.6 Hz, J= 1.2 Hz), 7.59 (dd, 1H, ArH 
coum, J= 4.4 Hz, J= 4.4 Hz), 7.33 (dt, 1H, ArH pic, J= 8.8 Hz, J= 2.8 Hz), 7.24 (dd, 1H, ArH pic, J= 
6.0 Hz, J= 2.8 Hz), 6.01 (exch br s, 1H, NH), 5.22-5.34 (m, 1H, CHNH), 4.70-4.80 (exch br m, 1H, 
NH2), 3.77-4.37 (m, 15H, 2 x CH2CH2O + NCH2CH2O + OCH3 coum (overlapped, 4.12) + 2 x OCH3 
pic (overlapped, 3.97 and 3.96)), 3.66-3.74 (m, 1H, NCH-HCH2O), 3.44-3.49 (m, 1H, NCH-HCH2O), 
3.10-3.30 (m, 2H, (CH2)2CH2N), 1.32-1.68 (m, 15H, CH(CH2)3 + (CH3)3 Boc). LC-MS (ESI) calcd. 
for C40H47N5O13 805.8 (MW), found m/z 806.3 [M+H]
+, 828.3 [M+Na]+, tR= 2.1. 
Fmoc/Boc-dipicolinate (9). 1 (490.0 mg, 1.30 mmol),  DIPEA (0.68 mL, 3.92 mmol) and TBTU 
(629.0 mg, 1.96 mmol) were sequentially added to a stirred solution of Nα-Fmoc-Nε-Boc Lys (609.0 
mg, 1.30 mmol) in anhydrous DMF (10.0 mL) under N2 atmosphere. The reaction was carried out for 
6 h at room temperature. After removal of the solvent, the crude mixture was extracted with CH2Cl2 
and a saturated solution of NaHCO3. The organic layer was concentrated in vacuo and the residue 
was purified by flash column chromatography (eluent: CH2Cl2/CH3OH 95:5) to obtain 9 as a 
yellowish oil (1.0 g, 93.1% yield). 1H NMR (400 MHz, CDCl3) δ 8.31 (dd, 2H, ArH pic, J= 19.2 Hz, 
J= 2.8 Hz), 8.01 (d, 2H, ArH pic, J= 8.8 Hz), 7.69 (dd, 2H, ArH Fmoc, J= 5.2 Hz, J= 2.8 Hz), 7.53 
(d, 2H, ArH Fmoc, J= 7.2 Hz), 7.29-7.35 (m, 2H, ArH Fmoc), 7.19-7.25 (m, 3H, ArH Fmoc (2) + 
ArH pic (1)), 7.15 (dd, 1H, ArH pic, J= 6.0 Hz, J= 2.8 Hz), 5.71 (exch br d, 1H, NH), 4.74-4.80 (m, 
1H, CHCH2O), 4.58-4.65 (m, 1H, CHNH2), 4.19-4.37 (m, 6H, 2 x CH2CH2O + CHCH2O), 4.12 (t, 
1H, NCH-HCH2O, J= 7.2 Hz), 3.93-4.02 (m, 2H, NCH2CH2O), 3.92(s, 3H, OCH3), 3.91(s, 3H, 
OCH3), 3.65-3.73 (m, 1H, NCH-HCH2O), 2.95-3.07 (m, 2H, (CH2)2CH2N), 1.57-1.75 (m, 2H, 
CHCH2(CH2)2), 1.24-1.51 (m, 13H, CHCH2(CH2)2 + (CH3)3 Boc). LC-MS (ESI) calcd. for 
C44H51N5O11 825.9 (MW), found m/z 826.4 [M+H]
+, 848.4 [M+Na]+, 413.9 [M+2H/2]+, tR= 2.4. 
Amine dipicolinate (10). A procedure analogous to the one used for the synthesis of 3, using 9 (1.00 
g, 1.21 mmol) as starting material and CH3CN/piperidine 4:1 (12.0 mL), yielded pure 10 (730.0 mg, 
99.9% yield) as a white solid (mp= 83-85°C), after purification by flash column chromatography 
(eluent: CH2Cl2/CH3OH, gradient from 95:5 to 9:1). 
1H NMR (400 MHz, CDCl3) δ 8.26 (dd, 2H, 
ArH, J= 15.2 Hz, J= 2.8 Hz), 7.95 (dd, 2H, ArH, J= 7.6 Hz, J= 0.8 Hz), 7.19 (dd, 1H, ArH, J= 6.0 
Hz, J= 2.8 Hz), 7.95 (dd, 1H, ArH, J= 6.0 Hz, J= 2.8 Hz), 4.64-4.78 (m, 1H, CHNH2), 4.24 (t, 2H, 
CH2O, J= 5.2 Hz), 4.19 (t, 2H, CH2O, J= 5.2 Hz), 3.76-4.00 (m, 9H, NCH2CH2O  + NCH-HCH2O + 
2 x OCH3 (overlapped, 3.86 and 3.85)), 3.64-3.72 (m, 1H, NCH-HCH2O), 2.84-3.03 (m, 2H, 
(CH2)2CH2N), 1.73-1.81 (m, 1H, CHCH-H(CH2)2), 1.52-1.65 (m, 1H, CHCH-H(CH2)2), 1.19-1.48 
(m, 13H, CHCH2(CH2)2 + (CH3)3 Boc). LC-MS (ESI) calcd. for C29H41N5O9 603.7 (MW), found m/z 
604.3 [M+H]+, 626.3 [M+Na]+, 302.8 [M+2H/2]+, tR= 1.3.  
Boc-dipicolinate (11). HOBt (163.4 mg, 1.21 mmol), Et3N (0.23 mL, 1.69 mmol) and EDC (0.30 
mL, 1.69 mmol) were sequentially added to a stirred solution of 3-methoxy-5-oxocyclohex-3-ene-1-
carboxylic acid 8 (288.0 mg, 1.69 mmol) in anhydrous DMF (10.0 mL) under N2 atmosphere. A 
suspension of 10 (730.0 mg, 1.21 mmol) in anhydrous DMF (10.0 mL) was dropwise added and the 
reaction was carried out for 12 h at room temperature. After removal of the solvent under vacuum, 
the crude mixture was purified by flash column chromatography using CH2Cl2/CH3OH 95:5 as eluent 
to obtain 11 (900.0 mg, 98.4% yield) as a yellowish solid (mp= 78-80°C). 1H NMR (400 MHz, CDCl3, 
signals marked with * correspond to additional peaks due to the presence of a minor isomer) δ 8.21 
(dd, 2H, ArH, J= 16.0 Hz, J = 2.8 Hz), 7.93 (dd, 2H, ArH, J= 8.0 Hz, J= 1.6 Hz), 7.17-7.21 (m, 1H, 
ArH), 7.13 (dd, 1H, ArH, J= 5.6 Hz, J= 3.2 Hz), 5.17 (d*, 1H, CHCOCH3), 4.91-4.98 (m, 1H, 
CHNH), 4.74-4.85 (m*, 1H, CHNH), 4.21-4.31 (m, 2H, CH2O), 4.08-4.17 (m, 2H, CH2O), 3.84-4.00 
(m, 3H, NCH2CH2O  + NCH-HCH2O), 3.81(s, 3H, COOCH3), 3.80 (s, 3H, COOCH3), 3.56-3.64 (m, 
1H, NCH-HCH2O), 3.52 (d*, 3H, CHCOCH3), 2.79-2.97 (m, 3H, NHCOCH + (CH2)2CH2N), 2.61-
2.69 (m, 1H, CHCH-HCO), 2.22-2.43 (m, 3H, CHCH2CO + CHCH-HCO), 1.44-1.63 (m, 2H, 
CHCH2(CH2)2), 1.14-1.37 (m, 13H, CHCH2(CH2)2 + (CH3)3 Boc). LC-MS (ESI) calcd. for 
C37H49N5O12 755.8 (MW), found m/z 756.4 [M+H]
+, 778.3 [M+Na]+, 378.9 [M+2H/2]+, tR= 1.6. 
Amine dipicolinate (12). TFA (5.0 mL) was slowly added to a stirred solution of 11 (1.45 g, 1.92 
mmol) in 10.0 mL of CH2Cl2 and the reaction was carried out for 2 h at room temperature. After 
removal of the solvent under vacuum, the crude mixture was purified by flash column 
chromatography (eluent: CH2Cl2/CH3OH/NH4OH 7:3:0.3) to give 12·TFA (1.36 g, corresponding to 
1.16 g of amine, 92.3% yield) as a brown viscous oil. 1H NMR (400 MHz, CD3OD, signals marked 
with * correspond to additional peaks due to the presence of a minor isomer) δ 8.33 (dt, 2H, ArH, J= 
15.2 Hz, J= 2.8 Hz), 8.04 (dd, 2H, ArH, J= 8.8 Hz, J= 5.6 Hz), 7.52 (d, 1H, ArH, J= 8.0 Hz), 7.45 
(dd, 1H, ArH, J= 6.0 Hz, J= 2.8 Hz), 5.37 (d*, 1H, CHCOCH3), 5.03-5.07 (m, 1H, CHNH (overlap 
CD3OD, ppm values from CDCl3 
1H NMR)), 4.35-4.51 (m, 2H, CH2O), 4.25-4.35 (m, 2H, CH2O), 
4.12-3.88 (m, 9H, NCH2CH2O + NCH-HCH2O + 2 x COOCH3 (overlapped, 3.95 and 3.94)), 3.75-
3.86 (m, 1H, NCH-HCH2O), 3.69 (d*, 3H, CHCOCH3), 3.02-3.14 (m, 1H, NHCOCH), 2.81-2.94 (m, 
2H, (CH2)2CH2N), 2.38-2.72 (m, 4H, 2 x CHCH2CO), 1.55-1.81 (m, 4H, CHCH2CH2CH2), 1.31-1.52 
(m, 2H, CHCH2CH2). LC-MS (ESI) calcd. for C32H41N5O10 655.7 (MW), found m/z 656.3 [M+H]
+, 
678.3 [M+Na]+, 328.8 [M+2H/2]+, tR= 1.0. 
Dipicolinate (14) - 1st synthetic approach. TFA (1.0 mL) was added to a stirred solution of 
intermediate 5 (85.0 mg, 0.10 mmol) in CH2Cl2 (2.0 mL). After 2 h at room temperature, the solvents 
were evaporated under vacuum to yield 6·TFA as a brown oil (85.0 mg, crude sample), which was 
directly used in the next step without further purification. HOBt (13.5 mg, 0.10 mmol), Et3N (0.02 
mL, 0.14 mmol) and EDC (0.025 mL, 0.14 mmol) were sequentially added to a stirred solution of 3-
methoxy-5-oxocyclohex-3-ene-1-carboxylic acid 8 (23.8 mg, 0.14 mmol) in anhydrous DMF (3.0 
mL). Intermediate 6·TFA (85.0 mg, 0.10 mmol) was added and the reaction was carried out for 48 h 
at room temperature under N2 atmosphere. After removal of the solvent under vacuum, the crude 
mixture was initially purified by flash column chromatography (eluent: CH2Cl2/CH3OH 95:5) and a 
following preparative HPLC purification was needed to obtain pure 14 (5.0 mg, yield 5.8% over 2 
steps) as a thick yellow oil. 1H NMR (400 MHz, CDCl3, signals marked with * correspond to 
additional peaks due to the presence of a minor isomer) δ 8.71 (exch br t, 1H, NH), 8.67 (d, 1H, ArH 
coum, J= 6.4 Hz), 8.27 (dt, 2H, ArH pic, J= 19.6 Hz, J= 2.4 Hz), 8.00 (dd, 1H, ArH pic, J= 7.6 Hz, 
J= 1.2 Hz), 7.97 (d, 1H, ArH pic, J= 8.8 Hz), 7.50 (t, 1H, ArH coum, J= 8.8 Hz), 7.22-7.25 (m, 1H, 
ArH pic), 7.18 (dd, 1H, ArH pic, J= 6.0 Hz, J= 2.8 Hz), 6.81-6.85 (m, 1H, ArH coum), 6.73 (t, 1H, 
ArH coum, J= 2.4 Hz), 5.23 (d*, 1H, CHCOCH3), 4.90-4.99 (m, 1H, CHNH), 4.26-4.40 (m, 2H, 
CH2O), 4.13-4.23 (m, 2H, CH2O), 4.01-4.12 (m, 1H, NCH-HCH2O), 3.91-4.02 (m, 2H, NCH2CH2O), 
3.87 (s, 3H, COOCH3), 3.85 (s, 3H, COOCH3), 3.81 (d*, 3H, PhOCH3), 3.59-3.70 (m, 1H, NCH-
HCH2O), 3.54 (d*, 3H, CHCOCH3), 3.22-3.41 (m, 2H, (CH2)2CH2N), 2.91-3.02 (m, 1H, NHCOCH), 
2.65-2.72 (m, 1H, CHCH-HCO), 2.29-2.49 (m, 3H, CHCH2CO + CHCH-HCO), 1.63-1.77 (m, 2H, 
CHCH2(CH2)3), 1.44-1.61 (m, 2H, CH(CH2)2CH2), 1.29-1.42 (m, 2H, CHCH2CH2). LC-MS (ESI) 
calcd. for C43H47N5O14 857.9 (MW), found m/z 858.3 [M+H]
+, 880.3 [M+Na]+, 429.8 [M+2H/2]+, 
tR= 1.7. HR-MS (ESI) calcd. for C43H48N5O14 858.3198 [M+H]
+, found m/z 858.3203. 
Dipicolinate (14) - 2nd synthetic approach. DMAP (14.5 mg, 0.12 mmol), 13 (358.9 mg, 1.13 mmol) 
and DIPEA (0.41 mL, 2.38 mmol) were sequentially added to a stirred solution of 12 (780.9 mg, 1.19 
mmol) in anhydrous CH2Cl2 (5 mL) and the reaction was carried out under N2 atmosphere for 10 h at 
room temperature. Additional DMAP (14.5 mg, 0.12 mmol), DIPEA (0.41 mL, 2.38 mmol) and 13 
(50.0 mg, 0.16 mmol) were added and the mixture was stirred for further 12 h. After evaporation of 
the solvent under vacuum, the crude was directly purified by flash column chromatography using 
CHCl3/CH3OH 9:1 as eluent, affording 14 (1.00 g, 98.4% yield) as an oil. 
1H NMR, LC-MS and HR-
MS match the characterization described above for 14 obtained through the “1st synthetic approach”. 
Dipicolinic acid (15) – ‘free’ ligand. LiOH (24.7 mg, 1.03 mmol) was added to a stirred solution of 
14 (221.5 mg, 0.26 mmol) in THF (3.0 mL), CH3OH (1.2 mL) and H2O (1.2 mL). The reaction was 
stirred for 16 h at room temperature. After evaporation of the solvents, 1N HCl (3.0 mL) was added 
and the mixture was stirred for additional 6 h. 6N NaOH was slowly added until pH= 5 and solvents 
were then evaporated. The crude product was initially purified by reverse-phase column 
chromatography (eluent: CH3OH/H2O 1:1) and a following preparative HPLC purification was 
needed to obtain pure 15 (14.0 mg, yield 11.3% over 2 steps, one-pot) as a sticky yellowish solid. 1H 
NMR (400 MHz, CD3OD + D2O, signals marked with * correspond to additional peaks due to the 
presence of a minor isomer) δ 9.00 (exch br s, 1H, NH), 8.74 (s, 1H, ArH coum), 8.29 (dd, 2H, ArH 
pic, J= 21.6 Hz, J= 2.8 Hz), 8.07 (dd, 2H, ArH pic, J= 8.8 Hz, J= 4.0 Hz), 7.69 (d, 1H, ArH coum, 
J= 8.8 Hz), 7.53 (dd, 1H, ArH pic, J= 6.0 Hz, J= 2.8 Hz),  7.48 (dd, 1H, ArH pic, J= 6.0 Hz, J= 2.8 
Hz), 7.00 (dd, 1H, ArH coum, J= 6.4 Hz, J= 2.4 Hz), 6.94 (d, 1H, ArH, J= 2.4 Hz), 5.37 (s,* 1H, 
CHCOCH3 (‘enol form’)), 4.97-5.04 (m, 1H, CHNH), 4.40-4.50 (m, 2H, CH2O), 4.34 (t, 2H, CH2O, 
J= 5.6 Hz), 4.02-4.13 (m, 3H, NCH2CH2O + NCH-HCH2O), 3.94 (s, 3H, PhOCH3), 3.72-3.80 (m, 
1H, NCH-HCH2O), 3.40 (t, 2H, (CH2)2CH2N, J= 5.6 Hz), 3.06-3.14 (m, 1H, NHCOCH), 2.66 (s,* 
2H, COCH2CO (‘keto form’)), 2.53-2.62 (m, 2H, CHCH2CO), 2.40-2.48 (m, 2H, CHCH2CO), 1.73-
1.85 (m, 2H, CHCH2(CH2)3), 1.57-1.67 (m, 2H, CH(CH2)2CH2), 1.41-1.54 (m, 2H, CHCH2CH2). 
13C 
NMR (100 MHz, CD3OD) δ 175.1 (2C), 175.0 (C), 168.1 (C), 166.8 (C), 166.7 (C), 164.5 (C),  163.3 
(C), 158.9 (C), 158.7 (C), 157.8 (2C), 149.8 (CH), 142.1 (C), 141.9 (C), 138.3 (2CH), 132.6 (CH), 
127.7 (2CH), 123.00 (CH), 122.8 (CH), 115.4 (CH), 114.9 (C), 113.4 (C), 111.2 (C), 101.2 (CH), 
99.2 (CH*), 68.1 (CH2), 67.5 (CH2), 56.9 (CH3), 50.87 (CH), 48.9 (CH2), 48.3 (CH2), 47.3 (CH2), 
41.0 (CH), 40.1 (CH2*), 36.1 (CH2), 35.6 (CH2), 32.5 (CH2), 29.6 (CH2), 23.8 (CH2). LC-MS (ESI) 
calcd. for C40H41N5O14 815.8 (MW), found m/z 816.3 [M+H]
+, 838.3 [M+Na]+, 408.8 [M+2H/2]+, 
tR= 1.3. UV-vis (H2O): λ/nm 290, 353. Fluorescence (H2O): λmax(ex) 350 nm, λmax(em) 407 nm; ФF 
= 0.11. HR-MS (ESI) calcd. for C40H42N5O14 815.2728 [M+H]
+, found m/z 816.2727. 
Chiral HPLC analyses of 15 were performed using Lux Amylose-1, Lux Cellulose-1, and Lux 
Cellulose-3 columns (150 x 2 mm, 3 µm I.D.; Phenomenex, Bologna, Italy) having amylose tris(3,5-
dimethylphenylcarbamate), cellulose tris(3,5-dimethylphenylcarbamate), and cellulose tris(4-
methylbenzoate) as chiral stationary phases respectively. All chromatographic resolutions were 
performed at 25°C using isocratic elution and mixtures of n-Hex/IPA or CH3CN/IPA 90:10 as the 
polar modifier. The dead times (t0) of the columns, estimated at flow rate of 1.0 mL/min, were 
comparable in the range of 0.9–1.0 min. From the analysis of the chromatogram obtained in analytical 
enantioseparations (Figure S1), we found that the chromatographic profiles of ligand 15 show only 
one main peak (> 95%) in all the three stationary phases tested, confirming that the S configuration 
of the L-Lysine is unchanged in the full synthetic pathway. 
VO(pic)2 complex (16). A solution of VOSO4·3H2O (15.2 mg, 0.07 mmol) in HPLC-grade H2O (1.0 
mL) was added dropwise to a stirred solution of 15 (57.0 mg, 0.07 mmol) in HPLC-grade H2O (3.0 
mL). 1M NaHCO3 was added to adjust the pH to 5 and the reaction mixture was stirred for 4 h at 
room temperature. After 24 h, a precipitate formed which was recovered by filtration under vacuum 
to give 16 (40.0 mg, 51.8 % yield) as a dark green solid. MS (MALDI) calcd. for C40H39N5O15V 
880.7 (MW), found m/z 880.5 [M]+, 881.5 [M+H]+. MS (ESI) calcd. for C40H39N5O15V(HCOO), 
925.7 (MW), found m/z 925.6 [M]+, 947.6 [M+Na]+, 963.6 [M+K]+. IR: νmax (neat)/cm-1 3297 (OH), 
2920 (NH), 1594 (CO), 969 (VO). UV-vis (DMSO): λ/nm 325. Fluorescence (DMSO): λmax(ex) 350 
nm, λmax(em) 409 nm; ФF = 0.04. Anal. calcd. for C40H39N5O15V(HCO3)·9H2O: C, 44.6; H, 5.3; N, 
6.3. Found: C, 44.2; H, 5.0; N, 6.4.  
VO(pic)2 complex 16 has been further analysed on a UPLC-MS/MS instrument consisting of a Waters 
ACQUITY liquid system equipped with a vacuum degasser, a binary pump, an autosampler and a 
thermostatted column compartment coupled to a Xevo TQ-S triple quadrupole mass spectrometer 
with an electron spray ionization source (ESI). The mass spectrometer was operated in positive ion 
mode and data were acquired using MassLynx V4.1 software. Analyses were conducted via direct 
injection in scan mode from 350 to 1000 m/z. Mass spectrometric conditions were as follows: 
capillary voltage 1.82 kV, source temperature 150 °C, desolvation temperature 150 °C, cone gas flow 
150 L/h, desolvation gas flow 600 L/h, collision gas flow 0.11 L/h and nebulizer gas flow 7.00 bar, 
cone voltage 68.00 V. MS (ESI) calcd. for C40H39N5O15V, 880.7 (MW), found m/z 904.4 [M+Na]
+, 
920.2 [M+K]+. 
UV-Vis and Emission Spectroscopy. General Remarks. The UV–vis spectra of the probes were 
recorded using a Perkin-Elmer Lambda 25 UV-vis spectrophotometer, while a Varian Cary Eclipse 
fluorescence spectrofluorimeter was used to record fluorescence emission spectra operating at a scan 
rate of 120 nm/min, using 0.05-0.1 mg/mL sample solutions and 1.0 cm path-length quartz cuvettes 
(1.0-3.0 mL) at 25°C. Spectra were not corrected for light intensity or detector sensitivity. Data were 
recorded on-line and analysed by Excel software on a PC computer. 
Fluorescence quantum yield. For these measurements quinine sulphate was adopted as standard 
because it absorbs at the excitation wavelength appropriate to the samples, and emit in similar spectral 
regions. In order to minimize re-absorption effects, absorbances in the 10 mm fluorescence cuvette 
were kept below 0.1 at the excitation wavelength. Spectroscopic grade solvents were used and 
checked for background fluorescence. The fluorescence of each sample was recorded in a range of 5 
concentrations (absorbance values in the range 0.02–0.1) and plots of integrated fluorescence 
intensity (IF) vs absorbance (A) were recorded. The gradient of each plot (IF vs A) is proportional to 
the quantum yield of the sample (see Figure S3, Supporting Information). For each test sample, the 
ФF value was obtained relevant to the standard and represents the quantum yield value reported. 
Biological studies on CBPs. Expression and Purification. PTP1B, VHR, SHP-2, PTEN and LMW-
PTP were expressed as GST-fusion proteins. The protocol used was as follow. The corresponding 
RNA was extracted using PureLink® RNA Mini Kit from Invitrogen (according to manufacturer’s 
protocol) from HEK293 cells. First DNA synthesis was performed using ProtoScript® First Strand 
cDNA Synthesis Kit from New England Biolabs according to manufacturer’s protocol. In a second 
round of PCR, gene specific primers were used to obtain the DNA for PTEN, PTP1B, VHR, SHP2 
and LMW-PTP, adding the restriction site BamHI at 5′ and XhoI at the 3′ end, respectively. The 
obtained coding regions of the respective DNA sequences were then cloned into pGEX-6P-1 vector 
using the aforementioned restriction sites. All four constructs were validated via DNA sequencing to 
ensure in-frame cloning with the GST tag encoded by the pGEX-6P-1 vector. Protein expression was 
induced in the E. coli strain DH5α for 24 h using 1 mM IPTG at 23° C. After growth the cells were 
harvested and stored at −20 °C. The harvested cells were resuspended in lysis buffer containing 50 
mM Tris (pH 7.4), 1% Triton X-100, 10 mM benzamidine hydrochloride, 100 μg per mL soybean 
trypsin inhibitor, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride and 2 mM DTT. 
Lysozyme was added to the cell suspension at a concentration of 2 mg/mL−1 and stirred for 1 h at 4 
°C. Lysis was completed by sonication, followed by centrifugation at 18 000g for 30 min at 4 °C. The 
supernatant was loaded onto a glutathione sepharose column, pre-equilibrated with 50 mM Tris (pH 
7.4), 140 mM NaCl and 2.7 mM KCl. After loading, the column was washed twice with 50 mM Tris 
(pH 7.4), 140 mM NaCl, 2.7 mM KCl and 2 mM DTT and 1% Triton X-100, another wash was 
performed using the same buffer without Triton X-100 and the final wash was carried out in the 
second buffer with 500 mM NaCl. The GST-tagged phosphatases were eluted using 20 mM 
glutathione in 50 mM Tris (pH 7.4), 250 mM NaCl and 2 mM DTT. 50% glycerol was added and the 
proteins were stored at −80 °C. Protein concentration was determined using Bradford assay. 
Phosphatase activity was determined by OMFP assay (as an example, see Figure S4 Supporting 
Information). 
Inhibition Assays (determination of IC50). 3-O-methylfluorescein phosphate (OMFP, 10 mM in 
DMSO) was diluted with a 1% DMSO solution to 200µM. The vanadyl complex 16 was dissolved in 
DMF to 1 mM and further diluted in water containing 1% DMSO to the required concentrations. 
Assays were run in 100 mM Tris (pH7.4) containing 1 mM DTT at room temperature. The inhibitor 
solutions were incubated with the enzyme in the buffer for 10 minutes at room temperature before 
reaction was initiated by addition of OMFP. Hydrolysis of OMFP to OMF was monitored by 
measuring changes in fluorescence over 30 minutes at 60 s intervals (excitation 485 nm, emission 
525 nm). Enzyme free blanks were run to eliminate background effects of OMFP hydrolysis in 
solution. 
Cellular uptake and oxidative damage in live cells. HCT116 cells were co-incubated with 100 nM 
PMA and 200 μM 16 (DMSO was used as a vehicle control) for 1-6 hours. For oxidative damage 
experiment, 0 or 1 mM H2O2 was added 30 min before the end of incubation. After this, cells were 
washed three times with PBS and fixed (ice-cold 70% EtOH) or detached by trypsinisation, 
resuspended in PBS and analysed by microscopy or flow cytometry, respectively. 
Flow cytometry and microscopy studies. Cell culture and stock solutions. HCT116 cells were 
cultured in McCoy’s media (HyClone) in an atmosphere of 5% CO2 at 37°C. All media was 
supplemented with 10% FBS (Invitrogen). 16 was dissolved in DMSO to a concentration 20 mM by 
5 min sonication. For cell assays, a final 200 μM solution was prepared in cell mixture. 
Cell viability: MTS assay. Cytotoxicity of complex 16 was measured by MTS assay (see Figure S8 
for data). HCT116 cells were seeded in 96-well plate at three concentrations of 2.25x104, 2x104, 
1x104 cells per well and were treated with mixture of [100 nM PMA + 16 at concentrations between 
10 μM and 200 μM] for 7.5, 24 and 48 hours respectively. MTS/PMS reagents were added according 
to manufacture recommendations (Promega, G5421) and cell viability was calculated after measuring 
the absorption at 490 nm (as % of the control, i.e. cells treated with PMA but without added 16). The 
results are shown as an average of triplicates ±SD using GraphPad Prism 7 software. 
Uptake and oxidative damage experiments. Flow cytometry. Live cells were treated with 25 μg/ml 
propidium iodide (PI, Sigma). Subsequently, cells were filtered through 38 µm nylon filter mesh 
(Baldwin Filters Ltd, UK) and analysed on Fortessa flow cytometer using the laser excitation at 355 
nm with 450/20 filter (for 16 uptake) and at 561 nm with 610/20 filter (for DNA profiles). From 
10000 to 15000 events per sample were acquired. Cell aggregates and debris were excluded by gating 
on dot plots of side scatter pulse area (SSC-A) vs forward scatter pulse area (FSC-A) and forward 
scatter pulse area (FSC-A) vs forward scatter pulse width (FSC-W). Single cells were also gated on 
PI-Width and PI-Area plots. Profiles were analysed by plotting UV-fluorescence intensity using 
FlowJo software (Tree Star Inc, USA). Non-stained samples were used as a control of 
autofluorescence. 
Microscopy. Fluorescence images were acquired using a Nikon Eclipse TE 2000-E inverted 
microscope and a PLAN FLUOR 40X air objective lens (NA = 0.60). A filter for UV2A (excitation 
wavelength 330-380 nm, long-pass emission wavelength 400 nm cut-on) was used and excitation 
light was provided by mercury lamp. Images of fixed cells were acquired using a Hammamatsu 
camera for each channel separately. Image analysis of mean fluorescence intensity was performed 
using Fiji-ImageJ. 
Statistical analysis. Statistical comparison of the means (using GraphPad Prism 7) was performed by 
two-way ANOVA or two-tailed test (with a 5% cut-off for significance). The degree of significance 
is indicated by stars (i.e. *p < 0.05; **p < 0.01; ***p < 0.001) within the corresponding figures. 
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Figure S1. Analytical chiral HPLC profiles of ligand 15. Stationary phases (columns): amylose 
tris(3,5-dimethylphenylcarbamate) (Lux Amylose-1), cellulose tris(3,5-dimethylphenylcarbamate) 
(Lux Cellulose-1), and cellulose tris(4-methylbenzoate) (Lux Cellulose-3); eluents: n-Hex/IPA and 
CH3CN/IPA 90:10; flow rate: 1.0 mL/min; temperature: 25°C; UV detection: 254 nm. 
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4. ESI-MS, MALDI, UV/vis and emission for VO(pic)2 complex 16 
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Figure S2. 51V NMR spectrum of 16 (3 mg)  recorded after 72 h in solution (DMSO-d6, ca. 400 μL). 
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Figure S3. Linear plots for the calculation of fluorescence quantum yields for 15 and 16. The gradient 
of each plot (IF vs A) is proportional to the quantum yield of the sample. For each test sample, the 
ФF value is obtained relevant to the standard (quinine sulphate) and represents the quantum yield 
value calculated. 
 
 
 
 
 
 
Figure S4. LMW-PTP activity (as an e.g. for all phosphatases) in the presence of OMFP as a 
substrate. Four slope lines represent measurements of OMFP hydrolysis in the presence of LMW-
PTP-GST (0.05 – 0.42 μg). Horizontal line corresponds to the background measurements in the 
absence of LMW-PTP. High values of the slopes indicate high LMW-PTP phosphatase activity. 
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Figure S5. IC50 curves (values nM ± standard deviation of triplicate repeats) of dimedone-based 
VO(pic)2 complex 16 for PTP1B (= protein-tyrosine phosphatase 1B), SHP-2 (= Src homology region 
2 domain-containing phosphatase-2), LMW-PTP (= low molecular weight protein tyrosine 
phosphatase), and VHR (= dual specificity protein phosphatase 3). 
 
 
 
 
 
 
 
 
Figure S6. IC50 curves (values nM ± standard deviation of triplicate repeats) of VO(pic)2 (reference 
compound, Figure 1 - main text) and new dimedone-based VO(pic)2 complex 16 for PTEN (= 
phosphatase and tensin homolog). 
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Figure S7. Live cell uptake of 16 (flow cytometry). Live HCT116 were treated with 10-200 μM of 16 
for 24 hours. Flow cytometry histogram (A) and dotplot (B) show no significant increase of 
fluorescence in HCT116 cells after 24 hours treatment with 16, indicating that there is no detectable 
uptake of 16 in live HCT116 cells. Untreated cells are shown in Red. 10000 cells were measured for 
each analysis. Autofluorescence was measured in the absence of 16 (0 μM). 
 
 
 
 
 
 
 
 
Figure S8. Cytotoxicity of 16. HCT116 cells were treated with 100 nM PMA and 0 - 200 μM of 16 for 
7.5, 24 or 48 hours. Cell viability was measured by MTS assay. Data shown in average of triplicates 
± SD%.  
 
 
 
 
 
 
  
20 
 
 
Figure S9. Live cell uptake of 16 + PMA (flow cytometry). Live HCT116 cells were co-treated with 
100 nM PMA and 200 μM of 16 for 1 and 6 hours. Flow cytometry histograms show increase of 
fluorescence in HCT116 cells after 6 hours co-treatment (i.e. PMA + 16), indicating that PMA 
treatment facilitates the uptake of 16 in HCT116 cells. Untreated cells are shown in Red. 10000 cells 
were measured for each analysis.  
 
 
 
 
 
 
Figure S10. Live cell uptake of 16 + PMA (microscopy). Live HCT116 cells were co-treated with 100 
nM PMA and 200 μM of 16 for 6, showing increase of fluorescence and indicating that PMA treatment 
facilitates the uptake of 16. Untreated cells are shown at 6 hours (i.e. no incubation with PMA + 16). 
Quantification of fluorescence signal was performed with FIJI. 
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Figure S11. Flow cytometry histogram of HCT116 cells incubated with 16 under oxidative conditions. 
Live cells were co-treated with 100 nM PMA and 16 (200 μM) for 6 hours following by addition of 0 
or 1 mM of H2O2 for 30 min. Cells treated with 1 mM H2O2 (Green) show an increase in fluorescence 
intensity compared to the control (i.e. no H2O2, Blue). Untreated cells (no 16, no H2O2) are shown in 
Red. 10000 cells were measured for each analysis.  
 
 
 
 
Figure S12. Emission spectra for 16 in the absence/presence of H2O2 for 30 min. A) Fluorescence 
emission of 16 (200 μM) in PBS. B) Fluorescence emission of 16 (200 μM) + 30% H2O2 (1mM) in 
PBS after 30 minutes.  
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